Eagle Asset Management Inc. Has $11.22 Million Stake in Genomic Health, Inc. (GHDX)

Eagle Asset Management Inc. lessened its position in shares of Genomic Health, Inc. (NASDAQ:GHDX) by 7.5% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 350,847 shares of the medical research company’s stock after selling 28,626 shares during the quarter. Eagle Asset Management Inc. owned about 1.01% of Genomic Health worth $11,220,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Wetherby Asset Management Inc. raised its position in shares of Genomic Health by 3.7% during the 2nd quarter. Wetherby Asset Management Inc. now owns 8,912 shares of the medical research company’s stock valued at $290,000 after buying an additional 317 shares during the period. Parametric Portfolio Associates LLC raised its position in shares of Genomic Health by 5.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock valued at $262,000 after buying an additional 441 shares during the period. The Manufacturers Life Insurance Company raised its position in shares of Genomic Health by 3.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock valued at $516,000 after buying an additional 520 shares during the period. Legal & General Group Plc raised its position in shares of Genomic Health by 11.4% during the 2nd quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock valued at $226,000 after buying an additional 710 shares during the period. Finally, American Century Companies Inc. raised its position in shares of Genomic Health by 0.9% during the 2nd quarter. American Century Companies Inc. now owns 127,294 shares of the medical research company’s stock valued at $4,143,000 after buying an additional 1,092 shares during the period. 89.67% of the stock is currently owned by hedge funds and other institutional investors.

In related news, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $31.47, for a total value of $157,350.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $32.51, for a total transaction of $44,831.29. The disclosure for this sale can be found here. Insiders sold a total of 21,379 shares of company stock valued at $676,131 in the last quarter. 46.20% of the stock is owned by insiders.

Shares of Genomic Health, Inc. (GHDX) opened at $30.10 on Friday. Genomic Health, Inc. has a 1-year low of $26.37 and a 1-year high of $34.02.

Several analysts have recently commented on the stock. Zacks Investment Research raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Friday, October 13th. ValuEngine lowered shares of Genomic Health from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. Canaccord Genuity reaffirmed a “buy” rating and set a $35.00 price target on shares of Genomic Health in a research report on Wednesday, September 27th. Jefferies Group reaffirmed a “hold” rating and set a $33.00 price target on shares of Genomic Health in a research report on Thursday, September 14th. Finally, BidaskClub raised shares of Genomic Health from a “sell” rating to a “hold” rating in a research report on Saturday, August 26th. Two investment analysts have rated the stock with a sell rating, seven have issued a hold rating and one has assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $32.67.

WARNING: This article was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/12/03/eagle-asset-management-inc-has-11-22-million-stake-in-genomic-health-inc-ghdx.html.

Genomic Health Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

What are top analysts saying about Genomic Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Genomic Health Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit